Traws Pharma Shares Promising Interim Results for COVID Treatment
Traws Pharma Inc. (NASDAQ: TRAW) has recently unveiled interim data from an ongoing randomized, open-label Phase 2 study focusing on ratutrelvir, a novel oral, ritonavir-free Mpro/3CL protease inhibitor. This significant step highlights the company's commitment to advancing treatments for COVID-19.
Clinical Trial Design and Patient Involvement
The clinical trial was structured as an active-controlled comparison against Pfizer Inc.’s (NYSE: PFE) Paxlovid (nirmatrelvir/ritonavir). It primarily assessed patient-reported symptom outcomes, safety, and practicality for real-world application. The analysis involved a total of 37 patients, with 25 individuals receiving ratutrelvir and 12 on Paxlovid.
Study Results Overview
Patients who were treated with ratutrelvir took 600 mg orally once a day for a span of 10 days, while those in the Paxlovid group followed a regimen of 300 mg nirmatrelvir and 100 mg ritonavir, administered twice daily for 5 days, as per the approved guidelines.
Efficacy Assessment in COVID Patients
The early findings from this interim analysis revealed that patients on ratutrelvir exhibited time-to-sustained symptom relief and resolution that appeared numerically close to the outcomes for those taking Paxlovid. This sustained alleviation was characterized as a self-reported relief of all COVID-19 symptoms lasting for four consecutive days.
Observations and Patient Safety
As the analysis progressed, it was noted that not all participants had finished the entire 28-day observation period. Consequently, no formal statistical comparisons were established; the findings remain primarily descriptive in nature. Importantly, no instances of COVID-19 symptom resurgence or virologic rebound have been reported among patients treated with ratutrelvir to date.
Comparative Outcomes and Monitoring
In the Paxlovid arm, however, one rebound event was documented (1 out of 12 patients; 8.3%), occurring shortly after the standard 5-day course was completed. Furthermore, a portion of patients treated with ratutrelvir—specifically six individuals, accounting for 16.2% of the interim cohort—were unable to receive Paxlovid due to contraindications or the risks of drug interactions.
Patient Experience and Tolerability
Despite these challenges, these particular patients displayed symptom improvement that was consistent with the overall observations noted in the broader ratutrelvir cohort. The analysis indicates that ratutrelvir has been well tolerated, with a lower incidence of adverse events compared to the group taking Paxlovid.
Conclusions from Chief Medical Officer
Robert Redfield, Chief Medical Officer at Traws Pharma, remarked on the findings: “The combination of early and sustained symptom improvement, extended dosing duration, absence of viral rebound observed to date, and favorable tolerability supports the strategic hypothesis that ratutrelvir may have utility in reducing post-acute sequelae of SARS-CoV-2 infection (Long COVID).”
Market Response to Findings
Reflecting these developments, TRAW stock is observed to be down 2.27%, trading at approximately $2.15 during premarket sessions on the last available check.
Frequently Asked Questions
What is ratutrelvir?
Ratutrelvir is an investigational oral, ritonavir-free Mpro/3CL protease inhibitor developed by Traws Pharma for treating COVID-19.
How does ratutrelvir compare to Paxlovid?
Interim data suggests that the efficacy of ratutrelvir is numerically comparable to that of Paxlovid, particularly in symptom resolution and alleviation.
What were the results of the Phase 2 trial for ratutrelvir?
The Phase 2 trial indicated that ratutrelvir has a similar symptom relief profile to Paxlovid with fewer adverse events reported.
Who participated in the study?
A total of 37 patients participated in the study, with 25 receiving ratutrelvir and 12 receiving Paxlovid.
What is the current market status of Traws Pharma's stock?
The stock was reported at about $2.15, showing a decrease of 2.27% prior to market opening.
